Trial Profile
A Randomized Phase III Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms LASOR
- Sponsors Novartis Pharmaceuticals
- 14 Jun 2015 Two-year follow-up results presented at the 20th Congress of the European Haematology Association.
- 08 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.